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C ongenital heart disease (CHD), which is present inaround 1.0% (1 in 110) of all live births in the United
States, is the most common birth defect.1–5 Deﬁned generally
as malformations present at birth that involve the heart or
major associated blood vessels, CHD includes a remarkably
heterogeneous group of chronic conditions, with very different
phenotypes, prevalence, risk factors, and outcomes. CHD is a
signiﬁcant contributor to birth-defect–related morbidity, mor-
tality, and healthcare costs6 in early life and increasingly
among adolescents and adults.7 Because of their broad
impact at the population level, a public health approach is
needed to address the challenges of these common, critical,
and costly conditions.8 We sought to create a framework to
address CHD from a population-based perspective, to serve
as a model for a public health agenda for the United States,
with a goal of improving the lives of those with or at risk for
CHD. This framework is complementary to previous work
outlining the Centers for Disease Control and Prevention’s
scientiﬁc priorities related to CHD,9 because implementation
strategies are also needed in addition to addressing gaps in
scientiﬁc knowledge.9–11
The CHD framework is a public health model for addressing
disease at the population level, which emphasizes monitoring,
interventions, and optimizing outcomes at the population
level. Core components of a public health model are: (1)
identifying or monitoring the occurrence and outcomes of a
condition over time and among different subgroups in the
population; (2) investigating factors that impact occurrence
and outcomes, speciﬁcally causes of disease and modiﬁers of
prognosis; (3) developing interventions and policies to reduce
risks and improve outcomes; (4) implementing interventions
and policies; and (5) evaluating the effectiveness of such
interventions and policies.12 These components are intercon-
nected in that improvements in each component lead to
improvements in the entire framework and success in
addressing public health challenges.
The main features of the public health framework for CHD,
presented in language appropriate for a lay audience, have
three key pillars: Identify and Investigate, Develop Interven-
tions and Policies, and Implement and Evaluate (Figure 1). The
scope encompasses everyone at risk for CHD or living with
CHD to underscore the need for equitable and universal
access to care delivery and services. In the following sections,
components are discussed, along with key issues identiﬁed by
the Congenital Heart Public Health Consortium (CHPHC) for
improved outcomes. Key opportunities to advance a public
health agenda for CHD are listed (Table 1).
Identify and Investigate
Identiﬁcation includes monitoring both prevalence and out-
comes—CHD prevalence at birth and across the life span as
well as survival, morbidity, and disability. At any age,
prevalence depends on both birth prevalence and survival.
Disparities in survival based on race or ethnicity, or associ-
ated factors such as socioeconomic status or parental
education, impact the prevalence of speciﬁc types of CHD
at different ages.13 Reliable population-based monitoring of
CHD requires several elements: operational case deﬁnitions
that are clear and consistent; a source population that is well
deﬁned in time and space; and a sustainable ascertainment
system of CHD occurrence and outcomes that is accurate,
complete, and timely. In the United States, there are
From the Boston Children’s Hospital, Boston, MA (K.J.J., J.K.K.); University of
Utah School of Medicine, Salt Lake City, UT (L.D.B.); University of Mississippi
Medical Center, Jackson, MS (A.C.); University of California San Francisco
Medical Center, San Francisco, CA (E.F.); Ann & Robert H. Lurie Children’s
Hospital of Chicago, IL (B.S.M.); Children’s Healthcare of Atlanta, Emory
University School of Medicine, Atlanta, GA (M.E.O.); Centers for Disease
Control and Prevention, Atlanta, GA (M.E.O., M.A.H.); Seattle Children’s
Hospital, Seattle, WA (K.K.S.).
Correspondence to: Kathy J. Jenkins, MD, MPH, Department of Cardiology,
Boston Children’s Hospital, 300 Longwood Ave, Farley 135, Boston, MA
02115. E-mail: kathy.jenkins@childrens.harvard.edu
J Am Heart Assoc. 2019;8:e009450. DOI: 10.1161/JAHA.118.009450.
ª 2019 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modiﬁcations or adaptations are made.
DOI: 10.1161/JAHA.118.009450 Journal of the American Heart Association 1
SPECIAL REPORT
well-established programs for monitoring CHD at birth. The
National Birth Defects Prevention Network has provided
guidance for monitoring 16 speciﬁc types of CHD among
births.14 In contrast, population-based monitoring of CHD
beyond infancy and childhood nationwide is much less
developed and has signiﬁcant gaps.15 These gaps pose a
major challenge for population-based public health programs
aimed at addressing the needs of people with CHD across the
life span. A fragmented system of care for those with CHD
contributes to this challenge, particularly for adults. The
situation in the United States is in contrast to a few
successful models of population-based monitoring of CHD
throughout the life span.16,17
Investigation includes epidemiological research to under-
stand key elements such as: (1) factors that increase or
decrease the risk of developing CHD and (2) factors, including
genetic factors, that modify outcomes in those born with CHD,
including survival, health, quality of life, societal integration, and
other long-term outcomes, such as neurodevelopmental and
psychosocial outcomes and reproductive health. Currently,
Figure 1. Congenital heart public health consortium public health framework for congenital heart
disease.
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most causes of CHD are not known. A large fraction of CHD is
thought to have a multifactorial etiology—that is, many cases
are thought to be caused by a variable andmostly undetermined
combination of environmental and genetic factors.18,19 Deter-
mining the nature and contribution of these factors to the risk of
developing CHD has proven remarkably difﬁcult. Nevertheless,
such research is crucial to design evidence-based interventions
aimed at primary prevention (reducing the number of newborn
cases of CHD)9 and secondary prevention (reducing
complications and improving outcomes for the many infants
who continue to be born with CHD).20 The population of
adolescents and adults with CHD continues to grow rapidly,
underscoring a need to investigate modiﬁable population-level
factors that can be leveraged to improve outcomes across the
life span. Recent evidence suggests ongoing risk for early
mortality, even after repair of less-severe CHD lesions.7
Multiple data sets are available and potentially useful to
examine CHD outcomes and health services utilization.21
Table 1. Key Opportunities to Advance Public Health for Individuals With Congenital Heart Disease
Identify and Investigate
Monitor
1 Initiate comprehensive population-based monitoring of the incidence, prevalence, morbidity and mortality of
congenital heart defects across the life span
Investigate determinants and modifiers
2 Leverage existing data to examine epidemiological and clinical factors associated with better
and worse health outcomes health service delivery
Develop Interventions and Policies
Unite and align
3 Design universally accepted policies and interventions to improve access to appropriate care, including specialty care and services
Reduce risk
4 Identify optimum timing of type of procedural medical intervention to inform treatment decisions in infancy, childhood, and adulthood
5 Research to identify strategies to reduce cardiac and noncardiac morbidity, including the brain, lungs, liver, and kidneys
6 Initiate practical, effective, and sustainable interventions for known modifiable risk factors for congenital
heart disease that have public health importance (eg, maternal pregestational diabetes mellitus)
Improve outcomes
7 Improve access to special education and/or other school-based interventions for all children with congenital heart
disease who have a neurodevelopmental impairment
8 Develop formal transition programs between pediatric and adult care and ongoing monitoring to assess the success or obstacles to transition efforts
9 Initiate programs to assure adequate support services for adults with neurocognitive decline
Equal access
10 Encourage insurance availability for congenital heart disease care across the life span, including specialty care when necessary
11 Develop programs to assure that all people with congenital heart disease have primary care in a patient-centered
medical home that includes supports to family members and caregivers
Implement and Evaluate
Prevention education
12 Target educational programs to individuals and the medical community to disseminate information about
proven and effective strategies to prevent congenital heart disease
Quality care
13 Project workforce necessary to care for the growing population of adults with congenital heart disease
and adjust the number of fellowship training programs and positions accordingly
14 Optimize healthcare systems with adequate specialty care for cardiac and noncardiac conditions to address
the needs of people with congenital heart disease
Evaluation
15 Develop and track key quality measures related to care for congenital heart disease and congenital
heart disease–related population health
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Key Issues Related to Monitoring
1. Infants with CHD are at increased risk for morbidity,
mortality, and developmental disabilities not only in
infancy, but also for decades later.13,22,23
2. Children and adults with CHD can develop problems in
numerous other organ systems, most notably the neuro-
logical,23–26 pulmonary,27 renal,28 gastrointestinal,29 and
hematologic/oncological30 systems. Adults with complex
CHD are at risk for lower functioning, achievement,
executive function, memory, language, social interactions,
and quality of life.31 Risk factors for brain injury are
cumulative and synergistic.32,33
3. There is no nation-wide system for monitoring the number
and health of people living with CHD.
4. There is no system to monitor outcomes of offspring of
people with CHD, or to monitor the outcomes of
pregnancies among women with CHD.
5. Limited information is available regarding racial, ethnic, and
socioeconomic characteristics of people living with CHD.
Key Issues Related to Investigating Determinants
and Modiﬁers
Primary Prevention
1. Nongenetic factors have been linked to increased risk for
CHD, including maternal conditions such as uncontrolled
pregestational diabetes, and pregnancy exposures, such
as some infections and medications.18,34–36 As a group,
however, recognized environmental or maternal risk fac-
tors still account for a small fraction, likely ≤10%, of
nonsyndromic CHD in the population.35–36 Most women
who give birth to children with CHD do not have or report
exposures to known risk factors; even among those who
report such exposures, the causal role of the exposure can
be difﬁcult to establish in any individual case.
2. Prenatal exposure to prescription opioids has been linked
to risk of some types of CHD,37 in addition to the well-
documented causal relationship with neonatal abstinence
syndrome. This type of risk factor with growing levels of
prenatal exposure merits additional research to better
understand the prevalence, timing, and correlates of
prenatal exposure linked to greatest risk for infants.
3. The proportion of CHD cases attributed to genetic causes
—chromosomal anomalies, genomic disorders (deletions
or duplications), and single-gene conditions—is still
unclear. Chromosomal anomalies alone seem to account
for 10% to 15% of cases of congenital heart defects.38,39
The risk of some of these chromosomal anomalies (eg,
trisomy 21, 18, and 13) are inﬂuenced by maternal age. As
a group, single-gene disorders (eg, the Noonan, Alagille,
and CHARGE syndromes) probably account for a much
smaller fraction of cases.38 However, recent ﬁndings
using more-advanced technology suggest that de novo
mutations and novel copy number variantsmay account for
an additional 10% to 15% of incident cases.40–42 What
remains largely unclear is to what extent genetic loci
contribute to disease risk and, in particular, to gene-
environment interactions that are modiﬁable by preventive
interventions.
Secondary Prevention
1. Appropriate timing for repeat interventional procedures is
not well established. Timing is important given that
delayed repair may lead to sequelae such as irreversible
myocardial dysfunction and arrhythmia. Conversely, pro-
cedures with limited durability may result in the need for
additional procedures over the life span.
2. Emerging data suggest that older individuals with CHD are
at increased risk for mortality, driven by coronary artery
disease, heart failure, and ventricular dysfunction.43
3. Risk for coronary artery disease is related to age,
hyperlipidemia, and hypertension.44 Certain types of
CHD, such as coarctation of the aorta, may increase the
risk for hypertension. Exercise restrictions may increase
the risk for obesity. Little is known about how to prevent
or treat acquired heart disease in people with CHD.
Develop Interventions and Policies
Public health interventions and policies that focus on CHD can
improve the health and well-being of people with CHD. Uniting
and aligning efforts among stakeholders should accelerate
effectively addressing CHD from a public health perspective.
The CHPHC was formed in 2009 as an organization of
stakeholders utilizing public health principles to affect change
for those with CHD at the population level (http://www.ch-
phc.org).10,11 The CHPHC has over 200 members, including
individuals and organizations, as well as liaisons from key
federal agencies (Table 2). The activities of the CHPHC are
coordinated by the American Academy of Pediatrics, with
support from the Centers for Disease Control and Prevention.
Since inception, the CHPHC has accomplished multiple
initiatives, such as assembling information to disseminate
key facts, identifying databases available for CHD surveillance
and research, and public awareness campaigns on various
topics related to CHD. The CHPHC can play a key role in
aligning efforts to advance a public health agenda to improve
lives for those affected by CHD.
To date, there are few speciﬁc policies or interventions
designed to reduce the impact of CHD on the US population.
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An exception is the implementation of newborn screening
using pulse oximetry to detect critical CHD at birth and
decrease infant mortality resulting from undiagnosed CHD.
Fortiﬁcation of cereals with folic acid, although aimed at
preventing other birth defects (ie, neural tube defects), may
prevent some CHD.18 Because of the many gaps in current
knowledge, more research—particularly translational
research—is needed. However, several important opportuni-
ties for primary and secondary prevention of CHD are
currently available based on what is already known about
modiﬁable risk factors.
Key Issues Related to Uniting and Aligning
1. Stakeholders interested in improving CHD outcomes across
the life span often work independently, without alignment.
Key Issues Related to Reducing Risk
1. Known modiﬁable risk factors for CHD include pregesta-
tional diabetes without adequate control, uncontrolled
maternal phenylketonuria, and maternal pregnancy expo-
sures, such as infections and the use of certain medica-
tions, continue to occur.
Key Issues Related to Improving Outcomes
1. Many children with CHD have difﬁculties in cognition,
language development, visual construction and perception,
visual motor integration, executive function, attention,
impulsivity, and ﬁne and gross motor skills.23 Poor
executive functioning is closely associated with lower
quality of life and school functioning in the CHD school-
aged population.45 Unrecognized or untreated neurodevel-
opmental impairments may lead to lower quality of life for
children with CHD.25,46,47
2. Children with CHD, particularly those with more-severe
forms, can be screened for neurodevelopmental impair-
ments.23
3. Adults with CHD also have altered cognition and neu-
ropsychological and neurological impairments48 that can
impact quality of life and workplace success.
4. Many adolescents and adults with CHD are not receiving
specialty care.49,50
Key Issues Related to Equal Access
1. Lack of healthcare providers with expertise in CHD,
including cardiologists and cardiac surgeons, can preclude
access, particularly in rural areas, or other geographical
locations.
2. Insurance barriers can preclude access to necessary care
for CHD, even when such care is available.
3. Unequal access to healthcare information related to CHD
care may cause individuals or families to not seek
appropriate care.
Implement and Evaluate
The measure of success of the public health approach
aimed at improving both primary and secondary prevention
is the extent to which it realizes a major reduction in the
health impact of CHD in the entire population. While
acknowledging that more research is needed, it is also
important to develop and implement solutions based on
what is already known. For example, maternal pregestational
diabetes mellitus is an established risk factor for CHD,51–53
and primary prevention targeting diabetes mellitus before
conception is possible today.54–56 It is also well established
that diabetic women who are in optimal glycemic control
immediately before and during pregnancy can reduce their
risk of having a baby with CHD to nearly the level of those
without pregestational diabetes mellitus.51,54,55 More con-
certed efforts could be undertaken to target screening
and management of diabetes mellitus among childbearing-
aged women at high risk of diabetes mellitus, with
Table 2. Congenital Heart Public Health Consortium Steering
Committee Member Organizations and Federal Liaisons
Steering Committee Members Federal Liaisons
Adult Congenital
Heart Association
Alliance for Adult Research
in Congenital Cardiology
American Academy
of Pediatrics
Section on Cardiology
and Cardiac Surgery
American College
of Cardiology
Adult Congenital & Pediatric
Cardiology Section
American Heart Association
Cardiovascular Disease
in the Young
Children’s Heart Foundation
Congenital Heart
Surgeon’s Society
National Birth Defects
Prevention Network
Mended Little Hearts
March of Dimes (2009–2017)
Pediatric Congenital
Heart Association
Society for Thoracic Surgeons
Centers for Disease Control
and Prevention
National Center on Birth Defects
and Developmental Disabilities
National Institutes of Health
National Heart, Lung, and
Blood Institute
Agency for Healthcare Research
and Quality Center for Quality
Improvement and Patient Safety
Health Resources and
Services Administration
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implementation of both individual- and population-level
interventions. These efforts would include increasing aware-
ness among childbearing-aged women and healthcare
providers about the risk of CHD associated with pregesta-
tional diabetes mellitus, as well as improving access to
screening and care for diabetes mellitus to increase the
proportion of childbearing-aged women with pregestational
diabetes mellitus in optimal glycemic control. Modeling has
estimated that 2670 congenital heart defects could be
prevented annually in the United States if interventions
succeeded in ensuring all women with pregestational
diabetes mellitus were in optimal glycemic control immedi-
ately before and during pregnancy.52
Similarly, secondary prevention should include compre-
hensive strategies with policy changes that improve
access to specialty care across the life span, such as
individual-level education of cardiologists and patients
regarding the importance of life-long specialty care. Pro-
grams to improve secondary outcomes may target speciﬁc
populations, such as implementation of neurodevelopmental
screening for all children with CHD, as well as neurocog-
nitive care and preventive care for adult patients as they
age.32
Evaluation is instrumental in demonstrating program
effectiveness and allowing effective pilot intervention pro-
grams to be expanded to reach a broader population. For
example, newborn screening based on pulse oximetry for
critical CHD in the United States began in 2011, and, as of
2015, 43 states had taken steps toward implementing
universal screening.57 The goal of critical CHD screening is
to reduce morbidity and mortality associated with delayed
diagnoses, and evaluation will be essential in quantifying
the impact of this public health intervention. Simi-
larly, screening children and adults with CHD for neurode-
velopmental/neurocognitive and psychosocial issues will
provide secondary prevention opportunities to reduce the
health impact of CHD on individuals over their entire life
span through appropriate therapeutic interven-
tions.23,32,33,48,58
Key Issues Related to Prevention Education
1. Few educational programs exist that are targeted to
individuals and the medical community about reasonable
strategies to prevent CHD, based on current knowledge.
Key Issues Related to Quality Care
1. Appropriately treating the medical and nonmedical needs
of children with CHD is difﬁcult. For providers, creating a
patient-centered medical home for children with CHD,
particularly those with complex disease, is particularly
important.59 For families, the toll on parents and siblings
can be burdensome.60
2. People with CHD begin to leave specialty care around age
8 years, over half are lost to follow-up by age
18 years,61,62 and >40% of adult CHD patients note a
prolonged gap in cardiology care, typically around age 19
to 20 years50,63; those with gaps in care are more likely to
have adverse outcomes.64,65
3. Transition of care from pediatric cardiologists to adult
cardiologists with expertise in CHD is inconsistent, and the
optimum transition practice is not known.
4. Accurate projections of the workforce needed to care for
the growing population of adults with CHD are lacking.
5. As neurodevelopmental sequelae in children with CHD
evolve to cognitive decline or dementia during adult-
hood, a growing population of individuals living with
CHD may require support services.
6. The American Board of Internal Medicine and American
Board of Pediatrics have recently established fellowships
in adult CHD, with different pathways and a board
examination. The Adult Congenital Heart Association is
developing program accreditation standards and center
accreditation is being piloted.
Summary and Recommendations
A public health framework is presented to guide a public
health agenda for CHD in the United States. The framework
includes: (1) identiﬁcation and investigation, including public
health monitoring systems and population-based research; (2)
development of interventions and policies, including aligning
stakeholders, creating public systems and policies to reduce
risk, improving outcomes, and ensuring equitable access and
utilization of care; and (3) implementation and evaluation,
including education and quality care programs; connecting
individuals, health care, and ancillary services; and evaluation
of systems. The CHPHC aligns key stakeholders as a public-
private partnership to reduce death and disability from CHD
across the life span. Collective efforts within the framework
by CHPHC members are addressing all components with
improved coordination (Figure 2). Key opportunities to
advance a public health agenda for CHD are listed in Table 1,
including opportunities for research, monitoring, and imple-
mentation. The CHD population is growing, with signiﬁcant
risks, comorbidities, and enhanced need for healthcare
resources. Knowledge gaps currently exist in many areas,
and few policies and programs are speciﬁcally designed to
reduce risk or improve outcomes for people with CHD. Future
efforts aligned with the framework should accelerate knowl-
edge and strategies to more rapidly reduce disease burden
and improve outcomes at a population level for those affected
by CHD.
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